Ionis Pharmaceuticals

IONS · NASDAQ

$45.40+$1.02 (+2.30%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $44.38

Latest news

Press releaseOct 20, 9:20 PM ETBusiness Wire
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Press releaseOct 16, 6:45 AM ETBusiness Wire
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
NewsSep 23, 8:13 AM ETVandana Singh
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Press releaseSep 23, 1:00 AM ETBusiness Wire
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
NewsSep 22, 12:11 PM ETVandana Singh
Ionis to Seek Expedited FDA Review for ALS Drug
NewsSep 22, 10:40 AM ETChandrima Sanyal
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Press releaseSep 22, 8:00 AM ETBusiness Wire
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
NewsSep 8, 10:19 AM ETKaustubh Bagalkote
Why Is Eli Lilly Stock Falling Tuesday?
NewsSep 8, 8:01 AM ETAvi Kapoor
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
NewsSep 8, 8:01 AM ETVandana Singh
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
NewsSep 8, 7:16 AM ET
Market-Moving News for September 8th
Press releaseSep 4, 4:41 PM ETBusiness Wire
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
NewsSep 4, 8:23 AM ETVandana Singh
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment
Press releaseSep 3, 7:47 PM ETBusiness Wire
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
NewsSep 3, 3:56 PM ET
FDA Approves Zanvastro For Treatment Of Alexander Disease
Press releaseSep 3, 7:05 AM ETBusiness Wire
Ionis to present at upcoming investor conferences
Press releaseAug 20, 7:00 AM ETBusiness Wire
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
NewsAug 18, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today’s Session
Press releaseAug 8, 4:07 PM ETBusiness Wire
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Press releaseAug 6, 11:02 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Press releaseAug 4, 5:15 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
NewsJul 30, 2:37 PM ETVandana Singh
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Press releaseJul 30, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
NewsJul 29, 1:36 PM ETVandana Singh
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Press releaseJul 29, 7:05 AM ETBusiness Wire
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
NewsJul 29, 7:02 AM ET
Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate
Press releaseJul 29, 7:00 AM ETBusiness Wire
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Press releaseJul 28, 5:03 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Press releaseJul 28, 12:46 PM ETGlobe Newswire
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
Press releaseJul 23, 11:30 AM ETPRNewswire
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS
Press releaseJul 23, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
Press releaseJul 9, 8:57 PM ETPRNewswire
Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)
NewsJul 9, 8:58 AM ETRishabh Mishra
Stock Market Today: S&P 500, Nasdaq 100, Dow Jones Futures Rise as US-Iran Exchange Strikes—Levi Strauss, AZZ, Ionis Pharma In Focus (UPDATED)
NewsJul 9, 8:02 AM ETAvi Kapoor
Levi Strauss, Ionis Pharmaceuticals, Gloo Holdings And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
NewsMay 11, 12:03 PM ETVandana Singh
GSK Targets China's Hepatitis B Market Through New Deal
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

Ionis to Seek Expedited FDA Review for ALS Drug

Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

Why Is Eli Lilly Stock Falling Tuesday?

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Market-Moving News for September 8th

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Ionis Drug Wins FDA Approval as First Alexander Disease Treatment

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

FDA Approves Zanvastro For Treatment Of Alexander Disease

Ionis to present at upcoming investor conferences

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

10 Health Care Stocks Whale Activity In Today’s Session

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate

Ionis reports second quarter 2026 financial results and highlights progress on key programs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

Stock Market Today: S&P 500, Nasdaq 100, Dow Jones Futures Rise as US-Iran Exchange Strikes—Levi Strauss, AZZ, Ionis Pharma In Focus (UPDATED)

Levi Strauss, Ionis Pharmaceuticals, Gloo Holdings And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

GSK Targets China's Hepatitis B Market Through New Deal

Earnings Scheduled For April 29, 2026